CEL NUCLEASE-Fc FUSION PROTEIN AND PREPARATION METHOD AND USE THEREOF
CEL I-Fc and CEL II (C72A)-Fc fusion proteins expressed in CHO cells address high error rates in DNA synthesis by simplifying purification and enhancing error correction, improving efficiency and reducing costs in gene synthesis.
WO2026103599A1PCT designated stage Publication Date: 2026-05-21WUXI BIOLOGICS (SHANGHAI) CO LTD +1
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- WUXI BIOLOGICS (SHANGHAI) CO LTD
- Filing Date
- 2025-11-06
- Publication Date
- 2026-05-21
AI Technical Summary
Technical Problem
Current DNA synthesis methods, such as solid-phase phosphoramidite synthesis, suffer from high error rates due to poor purity of mononucleotides and incomplete coupling reactions, leading to prolonged production cycles and increased sequencing costs, necessitating cost-effective error-correcting enzymes like CEL nucleases for improved efficiency.
Method used
Development of CEL I-Fc and CEL II (C72A)-Fc fusion proteins expressed in CHO cells, which simplify purification and maintain biological activity, enabling efficient error correction in gene synthesis.
Benefits of technology
The fusion proteins achieve high expression levels and simplify purification, effectively reducing errors in gene synthesis, thereby shortening production cycles and lowering costs.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure PCTCN2025132959-FTAPPB-I100001 
Figure PCTCN2025132959-FTAPPB-I100002 
Figure PCTCN2025132959-FTAPPB-I100003
Abstract
Provided is a fusion protein comprising a CEL nuclease fused to an Fc fragment. The designed CEL I-Fc fusion protein and CEL II (C72A)-Fc fusion protein molecules possess complete biological activity, effectively eliminating errors generated during the gene synthesis process.
Need to check novelty before this filing date? Find Prior Art